The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities
Open accessAbstract
T cells to enhance anti-tumor immunity. Our review highlights key issues impacting TCVs in clinical practice and reports on progress in development. We review the mechanism of action, immune-monitoring, dosing strategies, combinations, obstacles, and regulation of cancer vaccines. Most trials of personalized TCVs are ongoing and represent diverse platforms with predominantly early investigations of mRNA, DNA, or peptide-based targeting strategies against neoantigens in solid tumors, with many in combination immunotherapies. Multiple delivery systems, routes of administration, and dosing strategies are used. Intravenous or intramuscular administration is common, including delivery by lipid nanoparticles. Absorption and biodistribution impact antigen uptake, expression, and presentation, affecting the strength, speed, and duration of immune response. The emerging trials illustrate the complexity of developing this class of innovative immunotherapies. Methodical testing of the multiple potential factors influencing immune responses, as well as refined quantitative methodologies to facilitate optimal dosing strategies, could help resolve uncertainty of therapeutic approaches. To increase the likelihood of success in bringing these medicines to patients, several unique development challenges must be overcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“and several effector mechanisms to eliminate tumor cells.(14) TCVs engage both innate and adaptive immunity with the use of an adjuvant and antigen to trigger an innate and adaptive response, respectively.”
BackgroundImmunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Foundational pre-clinical work of tumor neoantigens led to the first proof-of-concept study in mice, which revealed that mice treated with a peptide-based neoantigen vaccine against mLama4 and mAlg8 using poly(IC) as an adjuvant conferred strong anti-tumor immunity and high response rates in treated animals.(48) Furth…”
BackgroundCD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 682
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 646
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628 · cited 1×
“Understanding how novel adjuvants, excipients, and carrier systems, such as nanoparticles, bacterial ghosts, heat shock proteins, or other vesicles (see Table 1), influence the ADME of personalized TCVs may provide insights to improve efficacy and/or safety.(87,90,91) Additional aspects related to interactions and use…”
BackgroundAlspach, E., Lussier, D. M., & Schreiber, R. D. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028480 · Cited by 603
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 423
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Lopes, A., Vandermeulen, G., & Préat, V. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1154-7 · Cited by 385
CD4+T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8633 · Cited by 384
Applied Biopharmaceutics and Pharmacokinetics
Bollish, S. J. (1981) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/38.9.1400 · Cited by 380
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Morris, L. G. T., Riaz, N., Desrichard, A., Şenbabaoğlu, Y., Hakimi, A. A., Makarov, V., Reis-Filho, J. S., & Chan, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.7067 · Cited by 299
Immuno-oncology drug development goes global
Xin Yu, J., Hubbard-Lucey, V. M., & Tang, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00167-9 · Cited by 260
Effect of vaccine administration modality on immunogenicity and efficacy
Zhang, L., Wang, W., & Wang, S. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1081067 · Cited by 255
Butterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D. K., Wang, H.-J., Elashoff, R. M., McBride, W. H., Mukherji, B., et al. (2003) · PubMed · Cited by 255
The dawn of vaccines for cancer prevention
Finn, O. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.140 · Cited by 254
Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations
Wang, Y., Zhu, H., Madabushi, R., Liu, Q., Huang, S., & Zineh, I. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1363 · Cited by 228
Wierecky, J., Müller, M. R., Wirths, S., Halder-Oehler, E., Dörfel, D., Schmidt, S. M., Häntschel, M., Brugger, W., Schröder, S., Horger, M. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3905 · Cited by 228
Vaccine adjuvants as potential cancer immunotherapeutics
Temizoz, B., Kuroda, E., & Ishii, K. J. (2016) · International Immunology · doi:10.1093/intimm/dxw015 · Cited by 227
Papachristofilou, A., Hipp, M. M., Klinkhardt, U., Früh, M., Sebastian, M., Weiss, C., Pless, M., Cathomas, R., Hilbe, W., Pall, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0520-5 · Cited by 227
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 217
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Gulley, J. L., Madan, R. A., Pachynski, R., Mulders, P., Sheikh, N. A., Trager, J., & Drake, C. G. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw261 · Cited by 215
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 215
The Human Vaccines Project: A roadmap for cancer vaccine development
Romero, P., Banchereau, J., Bhardwaj, N., Cockett, M., Disis, M. L., Dranoff, G., Gilboa, E., Hammond, S. A., Hershberg, R., Korman, A. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0685 · Cited by 194
Antigen kinetics determines immune reactivity
Johansen, P., Storni, T., Rettig, L., Qiu, Z., Der-Sarkissian, A., Smith, K. A., Manolova, V., Lang, K. S., Senti, G., Müllhaupt, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706296105 · Cited by 184
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., Van den Eynde, B. J., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 175
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer
Jager, D., Jager, E., & Knuth, A. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.9.669 · Cited by 168
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
Guo, Y., Lei, K., & Tang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01499 · Cited by 156
Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M., Zaks, T. Z., Frederick, J., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2523 · Cited by 144
GuhaThakurta, D., Sheikh, N. A., Fan, L.-Q., Kandadi, H., Meagher, T. C., Hall, S. J., Kantoff, P. W., Higano, C. S., Small, E. J., Gardner, T. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2334 · Cited by 139
Marshall, S., Madabushi, R., Manolis, E., Krudys, K., Staab, A., Dykstra, K., & Visser, S. A. G. (2019) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12372 · Cited by 138
Hassan, R., Alley, E. W., Kindler, H. L., Antonia, S. J., Jahan, T. M., Honarmand, S., Nair, N., Whiting, C. C., Enstrom, A. M., Lemmens, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0070 · Cited by 132
Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 126
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Gatti-Mays, M. E., Redman, J. M., Collins, J. M., & Bilušić, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1364322 · Cited by 119
The influence of microenvironment on tumor immunotherapy
Zhang, J., Shi, Z., Xu, X., Yu, Z., & Mi, J. (2019) · FEBS Journal · doi:10.1111/febs.15028 · Cited by 118
Determinant spreading and tumor responses after peptide-based cancer immunotherapy
Ribas, A., Timmerman, J. M., Butterfield, L. H., & Economou, J. S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00029-7 · Cited by 114
Duperret, E. K., Perales‐Puchalt, A., Stoltz, R., Hiranjith, G. H., Mandloi, N., Barlow, J., Chaudhuri, A., Sardesai, N. Y., & Weiner, D. B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0283 · Cited by 114
Therapeutic cancer vaccines: From initial findings to prospects
Song, Q., Zhang, C.-D., & Wu, X.-H. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.011 · Cited by 106
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 104
The perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97
Harmonization of Immune Biomarker Assays for Clinical Studies
van der Burg, S. H., Kalos, M. D., Gouttefangeas, C., Janetzki, S., Ottensmeier, C. H. H., Welters, M. J. P., Romero, P. J., Britten, C. M., & Hoos, A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002785 · Cited by 95
Therapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 87
Personalized cancer vaccines: Targeting the cancer mutanome
Zhang, X., Sharma, P. K., Goedegebuure, S. P., & Gillanders, W. E. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.073 · Cited by 79
Unique Strengths of ELISPOT for T Cell Diagnostics
Lehmann, P., & Zhang, W. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-325-7_1 · Cited by 77
Correlates of immune and clinical activity of novel cancer vaccines
van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 77
The effect of antigen dose on T cell-targeting vaccine outcome
Billeskov, R., Beikzadeh, B., & Berzofsky, J. A. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1527496 · Cited by 73
Immune Monitoring of T-Cell Responses in Cancer Vaccine Development
Keilholz, U., Martus, P., & Scheibenbogen, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2540 · Cited by 67
Hong, E., & Dobrovolskaia, M. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.005 · Cited by 61
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
Shembrey, C., Huntington, N. D., & Hollande, F. (2019) · Cancers · doi:10.3390/cancers11091217 · Cited by 56
The Impact of Early-Phase Trial Design in the Drug Development Process
Conaway, M. R., & Petroni, G. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0203 · Cited by 55
Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling
Rhodes, S., Knight, G. M., Kirschner, D. E., White, R. G., & Evans, T. G. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.01.017 · Cited by 50
Challenges towards the realization of individualized cancer vaccines
Türeci, Ö., Löwer, M., Schrörs, B., Lang, M., Tadmor, A. D., & Şahin, U. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0266-2 · Cited by 49
Bräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 48
Antonarakis, E. S., Small, E. J., Petrylak, D. P., Quinn, D. I., Kibel, A. S., Chang, N. N., Dearstyne, E., Harmon, M., Campogan, D., Haynes, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0638 · Cited by 43
Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
Fennemann, F. L., de Vries, I. J. M., Figdor, C. G., & Verdoes, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00824 · Cited by 43
Tumour heterogeneity: principles and practical consequences
Stanta, G., Jahn, S. W., Bonin, S., & Höefler, G. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1987-9 · Cited by 41
Madabushi, R., Benjamin, J. M., Grewal, R., Pacanowski, M. A., Strauss, D. G., Wang, Y., Zhu, H., & Zineh, I. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1457 · Cited by 39
Vaccines as an Integral Component of Cancer Immunotherapy
Schlom, J., & Gulley, J. L. (2018) · JAMA · doi:10.1001/jama.2018.9511 · Cited by 38
Next Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 37
Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.
Halioua-Haubold, C.-L., Peyer, J. G., Smith, J., Arshad, Z., Scholz, M., Brindley, D. A., & MacLaren, R. E. (2017) · PubMed Central · Cited by 34
Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy
Coventry, B. J. (2019) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135519862234 · Cited by 34
Sellers, R. S., Nelson, K., Bennet, B. M., Wolf, J. J., Tripathi, N., Chamanza, R., Lepage, M.-F. P., Adkins, K., Laurent, S., & Troth, S. P. (2019) · Toxicologic Pathology · doi:10.1177/0192623319875085 · Cited by 33
Rhodes, S., Guedj, J., Fletcher, H. A., Lindenstrøm, T., Scriba, T. J., Evans, T. G., Knight, G. M., & White, R. G. (2018) · npj Vaccines · doi:10.1038/s41541-018-0075-3 · Cited by 26
Design of clinical trials for therapeutic cancer vaccines development
Mackiewicz, J., & Mackiewicz, A. A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.069 · Cited by 25
Afrough, S., Rhodes, S., Evans, T. G., White, R. G., & Benest, J. (2020) · Vaccines · doi:10.3390/vaccines8010131 · Cited by 22
Janowitz, T., Lu, L., Yan, H., & Shyam-Sundar, V. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s65963 · Cited by 19
Therapeutic cancer vaccines: a long and winding road to success
Baxevanis, C. N., Papamichail, M., & Perez, S. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.852961 · Cited by 16
Engineering CD4+ T Cells to Enhance Cancer Immunity
Sillito, F. E., Holler, A., & Stauss, H. J. (2020) · Cells · doi:10.3390/cells9071721 · Cited by 15
Optimisation of anti-cancer peptide vaccines to preferentially elicit high-avidity T cells
Kumbhari, A., Kim, P., & Lee, P. P. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110067 · Cited by 12
Regulatory considerations for clinical development of cancer vaccines
Heelan, B. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.982999 · Cited by 9
ADME Processes in Vaccines and PK/PD Approaches for Vaccination Optimization
Gómez‐Mantilla, J. D., Trocóniz, I. F., & Garrido, M. J. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse558 · Cited by 7
Immunosenescence and Cancer Immunotherapy at Old Age: Basics
Fülöp, T., Witkowski, J. M., Hirokawa, K., Larbi, A., & Pawelec, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_77-1 · Cited by 4
Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility
Nuffel, A. M. T. V., Boudousquié, C., & Tuyaerts, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02032 · Cited by 2
Cited by
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Tao, L., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 284
Liang, J., Zhu, F., Cheng, K., Ma, N., Ma, X., Feng, Q., Xu, C., Gao, X., Wang, X., Shi, J., et al. (2023) · Advanced Materials · doi:10.1002/adma.202306158 · Cited by 84
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
“21,22 While early-phase trials have demonstrated sporadic induction of tumor-speci fi c T-cell responses, the fi eld confronts critical barriers to clinical translation, as evidenced by the limited number of advanced-phase trials achieving durable therapeutic endpoints.”
Influential
Metadata
- Authors
- Shemesh, C. S., Hsu, J. C., Hosseini, I., Shen, B.-Q., Rotte, A., Twomey, P., Girish, S., & Wu, B.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 29
- Issue
- 2
- Pages
- 555-570
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W3089759173
- Cited by
- 286
- References
- 93
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.